RSV Treatment in Adults
For immunocompetent adults with RSV infection, treatment is entirely supportive care—there is no role for antiviral therapy, and ribavirin should not be used. 1, 2
Supportive Care (Standard Treatment)
The cornerstone of RSV management in adults consists of:
- Hydration and fluids
- Antipyretics for fever control
- Supplemental oxygen when hypoxemia is present
- Advanced respiratory support as needed (high-flow oxygen, non-invasive ventilation, or mechanical ventilation for severe cases) 1, 3
Important caveat: RSV-induced wheezing should be distinguished from true bronchospasm. RSV typically causes respiratory tract thickening that does not respond to bronchodilators, so routine bronchodilator use is not recommended unless there is documented reversible airway obstruction 3.
Antiviral Therapy: Limited Role
Ribavirin is NOT recommended for routine use in adults with RSV. The evidence is clear on this:
- Aerosolized ribavirin was originally licensed based on reduced supplemental oxygen needs, but its use is severely limited by efficacy concerns, safety issues, and cost 4
- For immunocompetent adults, there is no established benefit
- For immunocompromised patients (hematopoietic stem cell transplant recipients, leukemia patients) with severe RSV lower respiratory tract disease, systemic ribavirin may be considered, though evidence remains limited 5
If ribavirin is used in high-risk immunocompromised patients with severe disease, dosing per the ECIL-4 guidelines is 5:
- Day 1: 600 mg loading dose, then 200 mg every 8 hours
- Day 2: 400 mg every 8 hours
- Day 3 onward: Increase to maximum 10 mg/kg every 8 hours
- Adjust for renal function (creatinine clearance 30-50 mL/min: maximum 200 mg every 8 hours)
Antibiotic Use: Exercise Restraint
Bacterial co-infection rates in RSV are low, yet antibiotic prescription rates remain inappropriately high. 3 Current evidence and antibiotic stewardship principles advise against routine antibiotic use, even in severe RSV cases, unless there is clear evidence of bacterial superinfection 3.
Prevention: The Real Advance
While treatment options remain limited, prevention has dramatically improved with three FDA-approved vaccines for adults ≥60 years (RSVPreF3, RSVpreF, and mRNA-1345) 6, 7, 2. Vaccination is the most effective pharmacological prevention strategy for older adults 8.
Clinical Pitfalls to Avoid
- Do not routinely test for RSV in adults with respiratory illness unless they are high-risk or severely ill—and even then, prioritize testing for influenza and COVID-19 first, as these have specific antiviral treatments 2
- Do not prescribe ribavirin for immunocompetent adults—it offers no benefit and has significant toxicity
- Do not assume wheezing equals bronchospasm—RSV causes airway inflammation that typically doesn't respond to bronchodilators
- Do not reflexively prescribe antibiotics—bacterial co-infection is uncommon despite high prescription rates
Future Outlook
Several promising antiviral compounds remain in development, including fusion inhibitors and nucleoprotein inhibitors 9, but these are years away from FDA approval 4. Until then, supportive care remains the standard, with prevention through vaccination being the most impactful intervention for reducing RSV disease burden in adults.